138 related articles for article (PubMed ID: 20562647)
1. Immunoexpression of Ezrin and CD44 in patients with osteosarcoma.
Boldrini E; Peres SV; Morini S; de Camargo B
J Pediatr Hematol Oncol; 2010 Aug; 32(6):e213-7. PubMed ID: 20562647
[TBL] [Abstract][Full Text] [Related]
2. Prognostic significance of immunohistochemical expression of ezrin in non-metastatic high-grade osteosarcoma.
Ferrari S; Zanella L; Alberghini M; Palmerini E; Staals E; Bacchini P
Pediatr Blood Cancer; 2008 Apr; 50(4):752-6. PubMed ID: 17886294
[TBL] [Abstract][Full Text] [Related]
3. Ezrin expression predicts survival in stage IIB osteosarcomas.
Kim MS; Song WS; Cho WH; Lee SY; Jeon DG
Clin Orthop Relat Res; 2007 Jun; 459():229-36. PubMed ID: 17353802
[TBL] [Abstract][Full Text] [Related]
4. Ezrin in osteosarcoma: comparison between conventional high-grade and central low-grade osteosarcoma.
Park HR; Jung WW; Bacchini P; Bertoni F; Kim YW; Park YK
Pathol Res Pract; 2006; 202(7):509-15. PubMed ID: 16677779
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of P-glycoprotein, HER-2/ErbB-2, p53, and Bcl-2 in primary tumor and metachronous lung metastases in patients with high-grade osteosarcoma.
Ferrari S; Bertoni F; Zanella L; Setola E; Bacchini P; Alberghini M; Versari M; Bacci G
Cancer; 2004 May; 100(9):1936-42. PubMed ID: 15112275
[TBL] [Abstract][Full Text] [Related]
6. Clinical value of signal transducers and activators of transcription 3 (STAT3) gene expression in human osteosarcoma.
Wang YC; Zheng LH; Ma BA; Zhou Y; Zhang MH; Zhang DZ; Fan QY
Acta Histochem; 2011 Jul; 113(4):402-8. PubMed ID: 20546860
[TBL] [Abstract][Full Text] [Related]
7. Intense cytoplasmic ezrin immunoreactivity predicts poor survival in colorectal cancer.
Elzagheid A; Korkeila E; Bendardaf R; Buhmeida A; Heikkilä S; Vaheri A; Syrjänen K; Pyrhönen S; Carpén O
Hum Pathol; 2008 Dec; 39(12):1737-43. PubMed ID: 18701134
[TBL] [Abstract][Full Text] [Related]
8. Expression of platelet-derived growth factor-alpha receptor in human osteosarcoma is not a predictor of outcome.
Sulzbacher I; Birner P; Dominkus M; Pichlhofer B; Mazal PR
Pathology; 2010 Dec; 42(7):664-8. PubMed ID: 21080877
[TBL] [Abstract][Full Text] [Related]
9. Clinical implications of Ezrin and CD44 co‑expression in breast cancer.
Ma L; Jiang T
Oncol Rep; 2013 Oct; 30(4):1899-905. PubMed ID: 23900701
[TBL] [Abstract][Full Text] [Related]
10. Clinicopathologic analysis of HER-2/neu immunoexpression among various histologic subtypes and grades of osteosarcoma.
Kilpatrick SE; Geisinger KR; King TS; Sciarrotta J; Ward WG; Gold SH; Bos GD
Mod Pathol; 2001 Dec; 14(12):1277-83. PubMed ID: 11743051
[TBL] [Abstract][Full Text] [Related]
11. Ezrin and alpha-smooth muscle actin are immunohistochemical prognostic markers in conventional osteosarcomas.
Salas S; Bartoli C; Deville JL; Gaudart J; Fina F; Calisti A; Bollini G; Curvale G; Gentet JC; Duffaud F; Figarella-Branger D; Bouvier C
Virchows Arch; 2007 Dec; 451(6):999-1007. PubMed ID: 17786474
[TBL] [Abstract][Full Text] [Related]
12. High level of ezrin mRNA expression in an osteosarcoma biopsy sample with lung metastasis.
Ogino W; Takeshima Y; Mori T; Yanai T; Hayakawa A; Akisue T; Kurosaka M; Matsuo M
J Pediatr Hematol Oncol; 2007 Jul; 29(7):435-9. PubMed ID: 17609619
[TBL] [Abstract][Full Text] [Related]
13. Vascular endothelial growth factor expression in untreated osteosarcoma is predictive of pulmonary metastasis and poor prognosis.
Kaya M; Wada T; Akatsuka T; Kawaguchi S; Nagoya S; Shindoh M; Higashino F; Mezawa F; Okada F; Ishii S
Clin Cancer Res; 2000 Feb; 6(2):572-7. PubMed ID: 10690541
[TBL] [Abstract][Full Text] [Related]
14. The Prognostic Role of Ezrin and HER2/neu Expression in Osteosarcoma.
Abdou AG; Kandil M; Asaad NY; Dawoud MM; Shahin AA; Abd Eldayem AF
Appl Immunohistochem Mol Morphol; 2016; 24(5):355-63. PubMed ID: 26067138
[TBL] [Abstract][Full Text] [Related]
15. Prognostic significance of E-cadherin and ezrin immunohistochemical expression in prostate cancer.
Musiał J; Sporny S; Nowicki A
Pol J Pathol; 2007; 58(4):235-43. PubMed ID: 18459457
[TBL] [Abstract][Full Text] [Related]
16. Expression change of ezrin as a prognostic factor in primary osteosarcoma.
Wang YF; Shen JN; Xie XB; Wang J; Huang G
Med Oncol; 2011 Dec; 28 Suppl 1():S636-43. PubMed ID: 20859706
[TBL] [Abstract][Full Text] [Related]
17. Expression of heat shock proteins in osteosarcomas.
Moon A; Bacchini P; Bertoni F; Olvi LG; Santini-Araujo E; Kim YW; Park YK
Pathology; 2010; 42(5):421-5. PubMed ID: 20632817
[TBL] [Abstract][Full Text] [Related]
18. Expression and prognostic relevance of centromere protein A in primary osteosarcoma.
Gu XM; Fu J; Feng XJ; Huang X; Wang SM; Chen XF; Zhu MH; Zhang SH
Pathol Res Pract; 2014 Apr; 210(4):228-33. PubMed ID: 24440098
[TBL] [Abstract][Full Text] [Related]
19. Metastatic osteosarcoma at diagnosis: prognostic factors and long-term outcome--the French pediatric experience.
Mialou V; Philip T; Kalifa C; Perol D; Gentet JC; Marec-Berard P; Pacquement H; Chastagner P; Defaschelles AS; Hartmann O
Cancer; 2005 Sep; 104(5):1100-9. PubMed ID: 16015627
[TBL] [Abstract][Full Text] [Related]
20. [Protein expression of Skp2 in osteosarcoma and its relation with prognosis].
Liao QD; Zhong D; Chen Q
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2008 Jul; 33(7):606-11. PubMed ID: 18667774
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
